Decheng Capital Global Life Sciences Fund IV, L.P.
10% Owner · Aardvark Therapeutics, Inc.
Every open-market stock purchase Decheng Capital Global Life Sciences Fund IV, L.P. has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. Insiders sell for many reasons, but they buy with their own money for one — this page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- AARD−62.3% vs price paidAardvark Therapeutics, Inc.
2 purchases totalling $20.0M at an average of $16.00 per share; the stock last traded at $6.03. See all insider buying in AARD →
Avg price paid$16.00Latest price$6.03Market cap$130.7M
Cluster participation
Buys that landed within days of other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Get alerted the next time Decheng Capital Global Life Sciences Fund IV, L.P. — or any insider — buys
We watch every Form 4 as it hits SEC EDGAR and alert you when insiders cluster into the same stock.
About this data
Figures are parsed from Decheng Capital Global Life Sciences Fund IV, L.P.'s Form 4 filings on SEC EDGAR (CIK 1834150) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.